Seelos' Single Dose Of SLS-004 Shows Reduction In Parkinson's Associated mRNA, Protein Expression

  • Seelos Therapeutics Inc SEEL has announced positive in vivo data demonstrating down-regulation of SNCA mRNA and protein expression from a study of SLS-004.
  • The SNCA gene has been implicated as a highly significant genetic risk factor for Parkinson's Disease (PD).
  • In addition, accumulating evidence has suggested that elevated alpha-synuclein levels (α-synuclein) are causative in the pathogenesis of PD. 
  • The cohort administrated with LV vector carrying one key repressor, KRAB-MeCp2, and gRNA targeted the mouse SNCA intron 1, produced a 27% reduction on SNCA mRNA and a 40% reduction in SNCA protein expression in the substantia nigra of the injected left hemisphere versus the right hemisphere.
  • The cohort administrated with LV vector carrying a different effector, DNMT3A, and the same gRNA showed a more subtle effect on both SNCA-mRNA and protein levels (an average of nearly 10% and 20% reduction, left vs. right, respectively).
  • SLS-004 is a novel epigenome-editing approach to modulate the expression of SNCA gene mediated by modification of DNA-methylation. 
  • Price Action: SEEL shares are down 9% at $2.63 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsParkinson’s Disease
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!